Overview
- The Federal Trade Commission filed a federal complaint on July 29, 2026 accusing Hims & Hers of deceptive privacy practices that triggered a one-day stock drop that erased about $970 million in market value.
- The FTC alleges Hims used embedded tracking pixels and customer-list matching to send customers' medical details to advertising platforms including Meta and Snap.
- Regulators also say Hims billed customers for prescriptions almost immediately after they submitted intake forms and used confusing cancellation flows that may violate the Restore Online Shoppers' Confidence Act.
- A securities class action (Velanki v. Hims & Hers) has been filed in the Northern District of California and multiple plaintiff firms are soliciting investors to seek lead-plaintiff status before the November 2, 2026 deadline.
- If the regulators' claims are upheld the company could face consumer remedies and financial penalties while investors may pursue recovery through the pending litigation as the cases move through pretrial and class-lead appointments.